AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38212850
Drug: Insulin resistance-related
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance-related features (IR)
Trial: 38212850
Drug: Higher triglyceride
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher triglyceride (TG) and lower estimated insulin sensitivity (eIS)
Trial: 38212850
Drug: Estimated insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estimated insulin sensitivity (eIS)
Trial: 38212853
Drug: Cognitive bias
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive bias modification training (CBMT) - 4-week, 8-session, tablet-delivered intervention
Trial: 38213401
Drug: Home-based telerehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based telerehabilitation (tele-physical/occupational therapy)
Trial: 38214239
Drug: Aspirin use
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin use ≤7 days of index stroke
Trial: 38214239
Drug: Control (non-aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non-aspirin users)
Trial: 38214256
Drug: Ridaforolimus-eluting stent
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridaforolimus-eluting stent with shortened dual antiplatelet therapy (DAPT) for 1 month for stable angina or 1 to 3 months for acute coronary syndrome at investigator's discretion.
Trial: 38214552
Drug: Oral TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TXA (2g) administered 2 hours before surgery and 4 hours after incision
Trial: 38214552
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (1g) administered 30 minutes before surgery and 4 hours after incision
Trial: 38214552
Drug: Oral TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TXA and Intravenous TXA
Trial: 38214710
Drug: Shatavari (26,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shatavari (26,500 mg/d fresh weight)
Trial: 38214795
Drug: Cysticlean™ 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysticlean™ 240 mg
Trial: 38214963
Drug: Rosie chatbot
RxNorm normalized name: Rose Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosie chatbot treatment group
Trial: 38215127
Drug: Angiopuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiopuncture therapy
Trial: 38215770
Drug: De-escalation to
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-escalation to narrower-spectrum antibiotics (ampicillin, trimethoprim-sulfamethoxazole, cefuroxime, cefotaxime, ceftriaxone, amoxicillin-clavulanic acid, ciprofloxacin, or ertapenem)
Trial: 38216183
Drug: Monthly quantitative
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly quantitative surveys and daily diaries
Trial: 38216189
Drug: AF screening
RxNorm normalized name: Canesten AF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AF screening enrichment using a risk prediction model (RPM) followed by 14 days of a continuous ECG patch
Trial: 38216198
Drug: Interruptive alert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interruptive alert for oral fluid restriction in patients treated with intravenous furosemide
Trial: 38216200
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (1650 mg daily)
Trial: 38216296
Drug: Continuous intrafemoral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intrafemoral thrombolysis (urokinase injection for 7 days)
Trial: 38216511
Drug: Flecainide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (150 mg per day in a single sustained-release dose) for 6 months
Trial: 38216511
Drug: Flecainide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (150 mg per day in a single sustained-release dose) for 3 months
Trial: 38216511
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (standard of care) for 6 months
Trial: 38216554
Drug: Carcinoembryonic antigen-expressing
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carcinoembryonic antigen-expressing oncolytic measles virus derivative (MV-CEA) administered at the resection cavity (Group A)
Trial: 38216554
Drug: Carcinoembryonic antigen-expressing
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carcinoembryonic antigen-expressing oncolytic measles virus derivative (MV-CEA) administered intratumorally on day 1, followed by a second dose in the resection cavity on day 5 (Group B)
Trial: 38216784
Drug: Gender-affirming hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gender-affirming hormone therapy for trans women
Trial: 38216784
Drug: Gender-affirming hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gender-affirming hormone therapy for trans men
Trial: 38217032
Drug: Upfront, early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upfront, early radiotherapy to ≤ 5 high-risk spine lesions plus standard-of-care systemic therapy (20-30 Gy of radiation in 2-10 fractions)
Trial: 38217032
Drug: Standard-of-care systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care systemic therapy
Trial: 38217039
Drug: Urine osmolality
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urine osmolality > 760 mosmol/kg or urine creatinine > 13 mmol/L
Trial: 38217039
Drug: Days with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days with urine output < 1 L
Trial: 38218194
Drug: Fexinidazole 600
RxNorm normalized name: fexinidazole 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexinidazole 600 mg once daily for 10 days (6.0 g total dose)
Trial: 38218194
Drug: Fexinidazole 1200
RxNorm normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexinidazole 1200 mg daily for 3 days (3.6 g total)
Trial: 38218194
Drug: Fexinidazole 600
RxNorm normalized name: fexinidazole 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexinidazole 600 mg daily for 3 days followed by 1200 mg daily for 4 days (6.6 g total)
Trial: 38218195
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day for 60 days (low dose group)
Trial: 38218195
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day for 15 days (short treatment group)
Trial: 38218195
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day for 60 days (control group)
Trial: 38218919
Drug: YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YAG laser vitreolysis (early treatment group)
Trial: 38218919
Drug: Sham laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham laser treatment (early treatment group)
Trial: 38218919
Drug: YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YAG laser vitreolysis (delayed treatment group)
Trial: 38218919
Drug: Sham laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham laser treatment (delayed treatment group)
Trial: 38218924
Drug: Low-dose quadruple
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose quadruple antihypertensives (irbesartan 75 mg + metoprolol 23.75 mg + amlodipine 2.5 mg + indapamide 1.25 mg)
Trial: 38218924
Drug: Standard-dose dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose dual antihypertensives (irbesartan 150 mg + amlodipine 5 mg)
Trial: 38218936
Drug: telephone-delivered Common
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telephone-delivered Common Elements Treatment Approach (t-CETA)
Trial: 38218979
Drug: VT1021 (11.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VT1021 (11.8 mg/kg, RP2D)
Trial: 38219157
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (Group C)
Trial: 38220413
Drug: Curcumin (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (three capsules of 500 mg of Curcuma longa extract, with 98.42 % total curcuminoids) for twelve weeks
Trial: 38220413
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three capsules of 500 mg of starch) for twelve weeks
Trial: 38221808
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg hydromorphone (Day 2)
Trial: 38221808
Drug: 0 mg,
RxNorm normalized name: Winrevair 60 MG, 2 Vial Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg, 2 mg and 8 mg hydromorphone (Days 3-5)
Trial: 38222312
Drug: Lymphodepletion therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphodepletion therapy consisting of cyclophosphamide (30mg/kg) for 2 days followed by Fludarabine (25mg/m2) and TILs infusion.
Trial: 38224478
Drug: OCH-NCNP1 (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCH-NCNP1 (3.0 mg, orally administered once weekly for 24 weeks)
Trial: 38224663
Drug: Definitive chemoradiation
RxNorm normalized name: ESIKA PRO HD COLOR HIGH DEFINITION COLOR SPF 20 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Definitive chemoradiation with a dose of 50.4 Gy in 28 fractions and a concomitant boost of 62 Gy in 28 fractions to the primary target volume (CTV-/PTV-T)
Trial: 38224706
Drug: IPTp with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPTp with dihydroartemisinin-piperaquine plus daily co-trimoxazole
Trial: 38224706
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus daily co-trimoxazole
Trial: 38224710
Drug: Daily co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily co-trimoxazole plus monthly dihydroartemisinin-piperaquine (3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for 3 days)
Trial: 38224710
Drug: Daily co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily co-trimoxazole plus monthly placebo
Trial: 38224710
Drug: Daily co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily co-trimoxazole plus monthly dihydroartemisinin-piperaquine
Trial: 38225549
Drug: nabiximols in
RxNorm normalized name: Nabiximols
DrugBank: Nabiximols (DB14011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nabiximols in combination with TMZ
Trial: 38225549
Drug: placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo in combination with TMZ
Trial: 38225579
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 17.5 mg weekly by subcutaneous injection for 12 months
Trial: 38225598
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oral favipiravir (3.6g on day 0 followed by 1.6g daily for 7 days)
Trial: 38225598
Drug: No study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study drug (Control)
Trial: 38225650
Drug: Sequential levofloxacin-based
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential levofloxacin-based treatment regimen
Trial: 38225650
Drug: High-dose dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dual therapy (proton-pump inhibitor and amoxicillin)
Trial: 38225952
Drug: 300 IR
RxNorm normalized name: ORALAIR 300 IR TAB,SL PKT 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IR HDM SLIT tablet
Trial: 38226507
Drug: Mobile application
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile application with just-in-time adaptive intervention promoting physical activity and lower-sodium food choices, including weekly goal setting.
Trial: 38226931
Drug: N-803 plus
RxNorm normalized name: (+/-)-N-methylephedrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-803 plus BCG therapy
Trial: 38227033
Drug: Toripalimab +
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab + chemotherapy
Trial: 38227308
Drug: MultiStem (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MultiStem (1.2 billion cells, intravenous)
Trial: 38227315
Drug: Health literacy-informed
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health literacy-informed discharge medication communication bundle (n=99)
Trial: 38227447
Drug: Intensification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification of antihypertensive therapy with maximally tolerated doses of a β-blocker, a long-acting dihydropyridine calcium channel blocker, and a renin-angiotensin system inhibitor.
Trial: 38227447
Drug: Adequate time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate time on dialysis of at least 4 hours for delivering an adequate dialysis dose.
Trial: 38227933
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin A (4000 IU/kg, maximum 250,000 IU)
Trial: 38228387
Drug: Combined standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined standard medical treatment (SMT) and endovascular thrombectomy (EVT)
Trial: 38229072
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein dose
Trial: 38229181
Drug: Transdiagnostic sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic sleep treatment (six sessions)
Trial: 38229199
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg octreotide subcutaneous depot (CAM2029) every 2 weeks (Q2W)
Trial: 38229199
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of SRL therapy at standard doses (octreotide LAR 30 mg or lanreotide ATG 120 mg every 4 weeks [Q4W])
Trial: 38229269
Drug: Damoctocog alfa
RxNorm normalized name: DAMOCTOCOG ALFA PEGOL
DrugBank: Damoctocog alfa pegol (DB14700)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Damoctocog alfa pegol (BAY 94-9027, Jivi) at 45 IU/kg every 5 days or 40 IU/kg twice-weekly
Trial: 38229356
Drug: Tofacitinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib monotherapy (masked methotrexate withdrawal)
Trial: 38229357
Drug: IBI303 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI303 (40 mg subcutaneous injection every 2 weeks)
Trial: 38229357
Drug: Adalimumab (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (40 mg subcutaneous injection every 2 weeks)
Trial: 38229392
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment with three Lactobacillus strains (Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, Lactobacillus plantarum DSM 15313; 1 x 10^9 CFU)
Trial: 38229914
Drug: Inhaled anesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled anesthetics after total intravenous anesthesia (TIVA)
Trial: 38231017
Drug: Prednisone (PDN)
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone (PDN) 1 mg/kg per day from days 0 to 28 (Arm A)
Trial: 38231017
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (HD-DXM) 40 mg per day for 4 days, every 14 days, for 3 consecutive courses (Arm B)
Trial: 38231079
Drug: Telmisartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (40 mg daily for 14 days) plus standard of care
Trial: 38231126
Drug: TC (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC (treatment choice)
Trial: 38231536
Drug: 8-week blended
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week blended intervention combining weekly face-to-face group sessions and a digital companion app
Trial: 38231590
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of urinary CD4 + T-cell counts with proteinase-3 ANCA levels
Trial: 38231621
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel applied daily
Trial: 38231621
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied daily
Trial: 38231623
Drug: Azithromycin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (20 mg per kilogram of body weight)
Trial: 38231624
Drug: Simnotrelvir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simnotrelvir plus ritonavir (750 mg of simnotrelvir plus 100 mg of ritonavir, twice daily for 5 days)
Trial: 38232249
Drug: Maintenance electroconvulsive
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance electroconvulsive therapy (M-ECT) with medication
Trial: 38232692
Drug: High BAT
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High BAT volume (≥20 mL)
Trial: 38232692
Drug: Low BAT
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low BAT volume (<20 mL)
Trial: 38232864
Drug: Psychological pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological pain treatments
Trial: 38233075
Drug: Treatment-induced minimal
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-induced minimal disease activity (MDA) at 6 months
Trial: 38233075
Drug: Baseline morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline morning cortisol <13.9 nmol/L
Trial: 38233083
Drug: No saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No saline therapy
Trial: 38233575
Drug: i.v. 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. 24 mg dexamethasone
Trial: 38233586
Drug: anti-CD19 CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-CD19 CAR T cell therapy (axicabtagene ciloleucel)
Trial: 38233586
Drug: standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care (salvage chemotherapy followed by hematopoietic transplantation)
Trial: 38233608
Drug: DROP-IN +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DROP-IN + LaproFlex combination
Trial: 38233784
Drug: Ballet-based dance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ballet-based dance programme (12 one-weekly sessions)
Trial: 38233810
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously every 3 weeks for up to 6 cycles
Trial: 38233816
Drug: Thymosin α1
RxNorm normalized name: chymosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin α1 (1.6 mg subcutaneous injections for 24 weeks, daily for the first 2 weeks, biweekly for the next 22 weeks)
Trial: 38233878
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) at 0.07 mg/kg/day initially, adjusted by trough levels
Trial: 38233878
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) at a maximum of 2000 mg/day
Trial: 38233885
Drug: IVIg (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (1.0 g/kg in open-label extension)
Trial: 38233908
Drug: CleverCap pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CleverCap pill bottle linked to the WiseApp (intervention)
Trial: 38234020
Drug: Mebendazole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole (50 mg/kg/day, 100 mg/kg/day, 200 mg/kg/day) with bevacizumab (10 mg/kg/dose) and irinotecan (150 mg/m2)
Trial: 39681895
Drug: Nthabi conversational
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nthabi conversational agent system for family planning education
Trial: 38234736
Drug: Nthabi conversational
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nthabi conversational agent system for folic acid education
Trial: 38235421
Drug: RC48 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RC48 2.0 mg/kg plus toripalimab 3 mg/kg, q2w
Trial: 38235421
Drug: RC48 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RC48 2.5 mg/kg plus toripalimab 3 mg/kg, q2w
Trial: 38235421
Drug: RC48 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RC48 2.5 mg/kg plus toripalimab 3 mg/kg, q2w (HER2-positive population)
Trial: 38235421
Drug: RC48 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RC48 2.5 mg/kg plus toripalimab 3 mg/kg, q2w (low HER2 expressing population)